Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns-Reference-Cited by-同舟云学术

Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns

Published:2013-10-11 Issue:4 Volume:32 Page:447-454
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Tanaka Makoto,Hashimoto Yoshitaka,Sekiya Noboru,Honda Naoki,Deacon Steve,Yamamoto Masanobu

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00774-013-0517-y.pdf

Reference30 articles.

1. Osteoporosis prevention, diagnosis, and therapy (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

2. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T (1995) Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 206:89–96

3. Stoch SA, Wagner JA (2008) Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83:172–176

4. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244

5. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM (1998) The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:32347–33252

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis;BMC Musculoskeletal Disorders;2017-06-19

2. An oral cathepsin K inhibitor ONO-5334 inhibits N- terminal and C- terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women;Bone;2015-12

3. Perspectives on osteoporosis therapies;Journal of Endocrinological Investigation;2015-01-11